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Despile many advances since its inception in humans in 1977. 
coronsry angioplarly continues lo be limited b! the problems of 
abrupt ar,eriaI closore and late re~~,emxIs. Ewessiw plalelo, 
depmitin a, the site of awioplasty ondoubledly plnys ao impar. 
lan, mk in the palhophysiology of both of lhese probkrm. 
Monoelonal antibodies and snake renom.dertrcd or s?nthetir 
pep(ides dire&d agalnsl P cmnmon protein reco@ition rpqocmx 
on !he platelet glycoprotein IIbnlla rexsplor arc correndy in ,he 
etiy stages of preclinical and clinical testing and hold promise or 
prererdinz ahrup, closure and ra,enmis bj inhibiting plarele, 
Lnclion. \Vhc,ber a”’ of these sppnb nil, ewnua,,) he wm- 
moo,> owd in clinical pm&e will depnd on their &were on the 
romplet pathophjsiokqg of tbew prohlerm and on their ~Aet? 
profile when administered to pstienb aho are likely to reeeiw 
other antithrnmbtic medications and who are instrumented for 
rarrmar! angioplast>. 
Despite improvements in coronary angiaplasty equtpmenl 
tit and patient selection criteria (?I and greater operator 
experience (31. and pos.,ibly becaux of expanding indica- 
tions foi Ihe application of lhis lechnique. cornnor) angw- 
plasty continues to be plagued by the complicsdon* of 
abrupt arterial closure and late restenour. The major &he- 
mic complications of death. cmer~ency coronar) arrerg 
bypaw surgery and myocardial infxction occur in 4’7 tu 15 
ofpatients (4.5) and nearly 50% ofall myocardial mfarctiwn 
that occur within I year of angioplasty iire in padcnts \\ho 
have an index procedure-related arterial clowc Ihl. Rc\t- 
cnosis. desoite a more indolent coune and a conz~derablv 
lower mon~lity rate. rdll occur\ in ?X% to 3X% of p;menA 
(7-10) and mw cost %I .? billion annuallv m the Umtcd State\ 
alanetlll. 
Excessive platelet depowiun 31 the rite of coronary 
angioplasty is thought to play an important role m the 
pathophyaiulagy of both abrupt closure and rcrtenosir. 
Platelet deposition occun within minute\ after mGmnl and 
medial di,ruplion cawed by helloon angioplasty t I?-11 and 
its extent is dependent on the degree of architectural diuup- 
lion and on local Row charactcriAc+. lndirccr evidence for 
the importance of platelet dcpo\itian in the cauwion of 
abrupt vessel clowe in human, i> provided bwh by enprr- 
imenIal \rudn (16) *hoamg rhar powerful ptacler mhlhitorq 
prerenr ahrup! closure I” ammal model> of halloon ango- 
plau! and hy the findings of randomized clinical trials Ii) 
that \hos a dccrcax in the incidcncc of ahruQ1 clowrc c\cn 
nith relati\el! weak antiplatelet agents. r\ngioxopy per- 
formed m a limited number of padem\ irilh threatened 
vc~wl ctowrc aiwr coronary angiopla\ty ha5 olmosl urn- 
formly viwdiled a>xxialed thrombus (17). The pathuph>v 
iolog of wtenoris is probably more complen I IX). hut 
po\tm~ory myointimal hgprplaGa in at least home animal 
model, dot\ not occur in the Qrcsence of profound Ihrom- 
hocytupema IFig. II t 1920). Stimulated platelets are known 
to wrete holh competence factori (for example. olatelet- 
dewed growth factor [?I)) and proprcc*ion factors (for 
example. cpidermal growth factor. beta-transfomdng rowth 
factor> 1221) that appear to he important in rhe Fmooth 
mwclc cell replication needed for arterial wound healing. 
Platelets do not act alone in these phenomena. The intcrac- 
lion betarcn plaleletr and elements of Ihe coagulation 
ca>ade to ,hc gene,i\ of thromhi ip shown in general terms 
in Figure 1. 
Platelet Adhesion, Shape Change, 
Aggregation and Secretion 
lmmedralely after balloon angioplosly plalele, adhekm 
occor~. which precedes shape chnnge and aggregation. and 
i* then folloued by xcretmn of alpha granule products that 
may wve a\ both chcmotac:ic and mitogenic influences for 
the precurwr const,tuenrs of ics~“osts (?3-251. Once 10~~1 
platele! granule release has begun. ahape change may pre- 
cede adhesmn and further secretion may precede aggrega- 
Inn. This general sequence. iis stimuli and the m&cuiar 
receptors mediating these responses we outlined in Figure 3. 
The imcractivc and polcntially synergistic eRect of multiple 
%imuli should be underscored. In panicular. thromboxane 
A2 and adenosine diphosphate IADP) stimulate further ad- 
hesion and aggregation. and thrombin is also a powerful 
stimulus for platelet activation 126). 
Under certain conditions. however. platelet aggregation 
does not appear to be a prerequisite for secretion of the alpha 
granule products that may be of critical importance in abrupt 
ve~hel cloxwc and restenosis (fibrinogen. van Willebrand 
factor. platelet-derived growth factor. transforming growh 
factor beta. epidcrmal growth factor. platelet factor 4. beta- 
Ihromboglobulin. libronectin. thrombospondin and olhersl. 
Such circum~lances include Glanzmann thrombasthenia 
wherein a congenital deficiency of the glycoprotein Ilb/llIa 
receptor exists 07). during competitive inhibition of the 
glycoprotein llbillla receptor by specific peptides or mono- 
clonal antibodies (28-30) and in the oresence of hich levels 
ofepincphrine (31) or complement proteins C Sb-9 i321. The 
implications of these findings oo the expected outcome 
achieved by blocking plalelet aggregation during coronary 
angioplasty are uncertain. 
Mechanism 01 plalelet adhesion to damaged arterial SUP. 
fare. When the integrity of the vascular cndothelial lining is 
disrupted. rubendothelial components rrollagen. van Wille- 
brand factor. thrombospondin. tibmnectinl are exposed to 
Rowing blood. Within a few seconds. platelets adhere to 
some of the macromolecules. thus initiating the hemoslatic 
event. Platelet adhesion may be stimulated by collagen. 
thmmbin. !hromboxane A,. ADP. epinephrine or several of 
these faclors acting in concert. The primary mechanism of 
platelet adhesion to damaged arterial surfaces at shear rates 
chamcleristic of injured coronary arteries I> I .oW lo I ,200/s 
1331) is a binding of van WiNebrand factor immobilized in the 
subendothelium to the platelet glycoprotein lb receptor. 
Secondary mechanisms include a binding mediated by the 
VLA-5. VLA-6 and glycoprotein IV receptors or by fi- 
bronectin to collagen direcdy. At the lower shear rates that 
are characteristic of good angioplasty results in very large 
coronary ~esscls. the van Willebrand factor-glycoprotein lb 
receptor interaction is weaker and the collagen.glycopmtein 
lailla receptor interaction may predominate (34.35). 
Platelet aggregation. This may be stimulated by collagen. 
thrombin. thromboxane A>. serotonin. ADP. platelet- 
activating factor. epinephrine or a combination of these 
factors. The primary mechanism of platelet aggregation is a 
linking of two platelets by fibrinogen bound to the platelet 
glycoprotein Ilb/llIa receptor. The glycoprotein llblllla 
receptor may also hind van Willebrand factor, tibronectin 
I361 or vitroncctin (37) and these factors appear to be 
relatively more important 10 aggregation at high shear rates 
138). An arginine-glycine-aspartic acid (RGD) sequence 
present on fibrinogen. van Willebrand factor and fibronectin 
Figure 2. Basic platelet-coagulation cascade 
interactions. ADP = adenosine diphos- 
ptlate: GP = *tycoprotein: PAF = platelet- 
activaling factor: TxA, = thmmboxane A,: 
vWF = “on Willcbrand factor. 
Figure 3. Platelet hrombin-injured artery interaction\. The corn. 
dex stimuli and mechanisms ofadhcrion. \h.ae chance. awes;mon 
anisms governi~~lhese imeroclioo~ and to the !xliooli of other 
platelel-lhmmbur a”la~o”,st~. AT = antohrombm: FOP\ = fibrin 
depmdation Qrduclr: PAI = Qlasmmogn acliv;aorinhibilnr: SK = 
rtreptokinase: t-PA = riwr-lype Ql;nmmogc~ x&ax: L!K = 
urokinase. Other abbrevialions as m F8pure 2. 
appears essemial to the binding of Ibe glycoprolein llblllla 
receptor (39-41). 
PltitkI sewtory granules. Pkdelctr c”ntain lhrre type\ 
of secretory granules: dense ~ranuler. zdphn granule\- and 
hydrolase-containing granules lpnmary lyroromca With 
respect 1” the rlrength of stimulus “ccctrary 1” induct 
secretion. the granules ddTer from each other. Alpha granule 
secretion may bc induced by low IcvcI\ of cc&n \limul.mng 
agents without concomilanl secretion from olher gr:mule, 
1421. Exocylosis of olphe pranuk pruduc!\ may he \timu- 
lated by coiiageen. thrumbin. lhromboww A,. ADP or 
epinephrine. Lysosomal \ecrebon uppenr~ to occw “nly 
after stimulation by collagen or thrombin. wherea dense 
granule secretion may be slimulaled by colla~cn. lhrombin 
or higher levels of thromboiane A,. ADP JT cpincphrine 
tar inhIbItor-I. alpha,-antiplasmm. hwdme-rich dvcoom- 
fem. high moiec&werght kininogen. alpha,-a&y&n 
and alpha.-m;~crodobulinl1441. Dense ~mnuks may ~ccretc 
ogen. libroneain. uoo Willebrand factor and vitronectin). 
Thi, receptor compler is a member of !he “cytoadhesion” 
or “inlcgrin” wperhmily. whose receptors bind ID adhcrire 
protem\ that contain a common peplide recognition se- 
quence. Ar&ly-A\p MiDI 149). This amino acid sequence 
may be buod in fibroneclin. fibrinogen. van Willebrand 
fsclor. vilrunrctin. thrombo>pondin and type I collagen. 
Olher members of the integrin receptor $roup include ieu- 
kocylc receQtorb LFA-I and MAC-I and the fibronectin. 
wtronectin and collagen recepl”rs (VLA-2. laMa) (50). 
fhe\c rece~rlors mediate a wide variety of cellular inrerac- 
lions. 
I%r ply< <,,,“<~;,I llbillh (Y ,,,, ple.~ h r/w IIIU\, ,rbwdmr 
plrrrh wll wwliu, prorriu. A normal plarelel contains 
apprown;~wly SMHX) receptor complexes that when acti- 
wed expre~ hindins rites for the adhesion glycoproteins 
(:I). Forlhcr receptor site% may be eriprewd on the platelet 
wfacc after the relca~e reaction IS?). The binding of fibrin 
ago. fihmnectin and van Willebmnd factor to the glycopm- 
two IlbMla receplor on aclivaled platelets is mutually 
cwhwivc. wggerting lhal these adhesive proteins either 
rhxr a cornmoo binding \ile or bind to a site thal afleclr the 
binding utc or sites for other adhesive proteins !53l. Because 
fihrmogcn I\ the most abundant of these proteins in placma 
and bmd\ wilh higher or comparable affinily wh respect I” 
other protems. it may be the preferred lipand in YIY’ 
although van Willebrand facror appears particularly impur- 
lanl under conditions of high shear (53). 
with Glanrmann thrombasthenia who suffer from mucocuta- 
neou~ bleeding (54.55). 
Monoclonal antibodies. Several investigators 156-W 
have immunized mice with intact platelets and isolated 
antibodies that inhibit the interaction between platelets and 
tibrinogm-coated bead>. Immunoprecipitation and immu- 
ooaffiniiv ourdication studies showed that the antibodies 
react wiih a region on the glycoprotein IIblIIIa receptor. The 
first of these antibodies to be useful clinically f IOE5) allowed 
for carrier detection and prenatal diagnosis of Glanzmann 
thrombast:.enia in patients at risk (59.60). However, lOE5 
did not react with nonprimale platelets. limiting ils preclin- 
ical development as a means to treat thrombotic disorders. 
The antibody 7E3 was subsequently found to have cross- 
reactivity with canine platelets and a cloned cell line wus 
established (611. The 7E3 antibody was then cleaved by 
pepsin into Flab’), fragments to minimize the risk of throm- 
bocytapenie due to Fc fra8mcnt binding to splenic macro- 
phages (621. and moot preclinical studies with 7E3 have used 
this F(ab’lz fragment. The Fab fragment iz also active and 
ha!, heen studied in both animals and humans. Other mono- 
clonal antibodies such as AP-2 and LJ-CP8 have also been 
identified (63). 
A~IGII-AsP (RGD) wptidor. Snake venoms are known 
to contain proreins that markedly inhibit platelet aggregation 
WI. Of these. the best characterized are derived from 
Trimereserur graminerrs. Eckis corinam, Agkismdon pis- 
cirnr~r.r. Agkisrrodon rhodosroma and Bilis &fans and are 
called trigramin. echistatin, applaggin, kistrin and bitan. 
respectively (65-69). These proteins share a cornman RIXJ 
sequence, which is also found on fibrinogen and fibranectin. 
and appears to mediate binding to the 8lycoprotein IIb/IIIa 
receptor. In vitro platelet aggregation is reversibly blacked 
to the greatest extent by echistatin and to a slightly lesser 
extent bv trieramin. aoolaeein. kistrin and bitan with ._ ..__ 
i+IO-‘M, which is a IWfold greater inhibition than that 
seen with A~~-GIY-A~D pentides 169.701. but a lesser inhibi- 
tion than seen& 81 iek~some monoclonal antibodies (30). 
Somewhat similar synthetic wntiden mav omvide even 
hisher affinities for the glyco$ein Ilbllila’receptor and 
hold promise for future clinicai work 170). The binding and 
platelet inhibitory effect of kistrin appears to he rapidly and 
fully reversible, in contrast to thal of a8atr. including aspirin 
(71). 7E3 161) and trigramin (65). and this may offer a 
potential safety advanrr+ However. occasional ;hrombo- 
cytapenia has been noted to occur after administration of 
many glycoprotein IIb/IIla antagonists and this is of poten- 
tial concern IColler B. personnl commtmication. 1990). 
Preclinical Invesfigarion 
Use ot 7E3 in a canine sa8!up!asiy n&e!. After complc- 
lion of primate studies with 7E3 thai suggested no serious 
acute or long-term toxicity to a dose of 8 mgikg (72.73). this 
powerful antiplatelet agent was evaluated under experimen- 
tal circumstances designed to mimic clinical states in which 
platelet activation is believed tn he of major importance 
(16.74.75). Bates et rd. (16) compared the effect of 7E3 with 
that of 325 me aspirin in a canine model of coronary 
angioplasty. The 7E’3 F&W, was administered in a single 
bolus inlection of 0.8 m&8. After balloon angioplasty. an 
externa~constrictor was applied to the left coronary artery to 
decrease hvueremic flow bv 50%. Coronarv thrombosis 
occurred in’& of seven aspihn-treated dogs cbmpared with 
none of the 7E3-treated dons. Platelet actxeeation to ADP 
decreased to 8% of the b&inc value yi the 7E3-treated 
animals compared with 61% of the baseline value in the 
aspirin-treated animals. They concluded that acute throm- 
bosis after experimental coronary angioplasty is a platelet- 
mediated response that can be prevented by the administra- 
tion of monoclonal antibodies directed against the platelet- 
glycoprotein IIb/IIIa complex. 
Use nf 7E3 In nlher experIcteti m&k. Glycoprotein 
IIh/IIIa antagonists may also be of use in the setting ofacute 
myocardial infarction. For instance. Gold et al. (74) showed 
that 7E3 increased the speed ofcoronary reperfusion when it 
was given with low doses of tissue plasminogen ativator 
M-PA) compared with r&PA alone in a canine model. In a 
similar model. Yasuda et al. (75) demonstrated that post- 
thrombolytic reocclusion could be prevented with 7E3. 
Preclinical evaluation of RVI peptides other than ex viva 
binding studies has been extremely limited. 
Inirial Clinical Experience With Glycoprotein 
Ilbllllo Antagonists 
Unstable angina. After completion of phase I studies in 
normal human volunteers demonstratsd a satisfactory acute 
safety profile and marked effect on ex viva markers of 
platelet aggregation. 7E3 FM’), underwent initial testing in 
patients with unstable angina and those undergoing elective 
coronary angioplasty. In 16 patients with unstable angina, 
patients received either 0.05, 0.10. 0.15 or 0.20 mglkg and 
had other antiplalelet agents and heparin withheld for the 
study period 176). At the highest dose. bleeding time was 
prolonged from 6.3 min at baseline sfudy to z-30 min at I h 
after injection and returned to normal within 24 h after 
injection. Ex viva platelet aggregation was reduced from 
M).S% at baseline study to 1.5% at I h after injection. At 
0.20 m&8.85% to WOW of the platelet glycopmtein IIb/IIIa 
receptors was bound to 7E3 F(ab’),. Proportionately lower 
antiplatelet effects and lesser glycoprotein IIWIIIa binding 
were observed at lower doses of 7E3 F(ab’), and were 
closely correlated. An inhibitory effect of 7E3 F(ab’), on in 
viva platelet thrombus formation was also suggested. Spon- 
taneous an8inal pain occurred in three patients within 24 h 
before injection of 7E3 F(ah’), and did not occur in any of 
these patients during the I2 h after injection. Angina re- 
turned in these patients only after the bleeding time bad 
returned to normal. None of the patients had spontancolr; 
bleeding associated with injection of the antibody. Two of 
the 16 patients given 7E3 F(ab’l, dcveloppd low titers of 
immunoplobulin IIglG antibodies specific for the murine 
antibody. 
This initial clinical expencncc wth 7E3 F(ab’l? ha\ 
shown that single dares of the antibody produce a dore- 
dependent inhibition of platelet function. which is com- 
pletely reversible over o 24 h period. So& doles suHic!cnt 
to bind over 85% of the platelet glycoprotein llb/llla reccp- 
ton produce profound platelet inhtbttiun and prolong the 
bleeding time to >30 min. In addition. mhibition of platelet 
function by 7E3 Flab’), is associated with relief of anginal 
pain in patients with unstable angina. Despite its potent 
antiplatelet effects. however. 7E3 Ftab’l, wvas well tolerarcd 
and was not aaociated with rpontanaow bleeding in thi:. 
relatively limited number of pati,:nts. 
Coronary angioplasty. Despite the apparent cofety of7E3 
Fab in patienls with angina. concern ha3 remained about 
pole&l bleeding complications in patients instrumented for 
elective corcmary angioplasty who may al,” need to recewe 
aspirin and heparin in clinicnt dosages. To evaluate the 
safety of 7E3 in this setting. Ellis et al. 177) recently studied 
7E3 10.10 to 0.35 m&t/kLI Fab in 27 pot~ts undergoing 
elective aogioplasty. Patients with ai incrca%d ri& of 
bleeding were excluded. Antio~larty was performed in the 
usual fashion. except that &&I was not &+a on the day of 
the procedure. There were no major bleed@ epwdes and 
the median decrease in hemoglobin did not differ between 
patients receiving placebo or 7E3. 
Titrated and precise dosing of 7E3 in the settmg of 
coronary angioplasty may be hampered by the experimenlal 
finding that abolition of thrombi nay be achieved at 7E3 
doses that do not markedly alter the bleeding time. Thus. in 
a primate carotid injury model. Caller et al. 1781 obrerved the 
abolition of thrombi at 7E3 doses that only modestly pro- 
longed bleeding time> and aggregation raponses to ADP and 
epinephrine. The percent of glycoprotcin llbillla receptors 
blocked appeared to correlate more closely with the in viva 
effect. 
The dwarion qf o,lrirr~~~‘,psv,,.? ~f7+fp(.1 ofo .sbqk disc O/ 
7U is dose dcpoidcvr. but appesrs unlikely to exceed 12 h 
at the doses most likely to be used in clinical trials. Given 
that the stimulus for platelet aggrcgotion in the setting of 
coronary aogioplasty may be present for n longer duration. 
multiple dose or continuous infusion regimens will likely be 
required. Extending the duration of ctTcct. however. may 
increase the risk of bleeding and extend the duration of 
patient hospitalization. Further studies are needed to deter- 
mine how an appropriate balance can be \lruck between the 
need for inhibition of plntelct aggrcaation and patient com- 
fort and safety. Duse-finding studies hew not yet been 
performed for RGD pepridec in a?imal models. 
An accurare apprecialion of the hkehhood of soccessfol 
clinicnl applrcation ofglycoprotein llhlllla antagonists to the 
problems of abrupt vessel closure and restenosis will depend 
oo on improved understanding of the pathophysiology of 
the\e problems and on the safety of these antagonists in the 
retting of elective coronary angioplasty. 
Glycoorotein llbllla antawttists to prevent or reat abrupt 
closure. It IS likely rhar pl&let dep&tion is rhe prim& 
mechanism of abrupt vessel closure m o minority of patients 
Igenerally patients with an cnstable clinica! syodromci and 
an important contributing mechanism in mm other patients. 
However. few clioical data exist o substantiate this soppo- 
smoo. wh,;h is based on ammal studies (1?.!5). preliminary 
an&copy wdies 117) and clinical inferences. Therefore. 
unless such axeots are nssociated with high rates of bleedina. 
it 1% likely I!% they may become valuthle as primary & 
secondary (with mechanical displacement of gross arterial 
disruptmns by ~tents or other meansl treatment for angio- 
pkwy-induced abrupt vessel closure. 
C.tpqlrotein llbma ntagnisls to prevent restena+% 
The mul!iple mechanisms and relatively prolonged tiote of 
development of restenosis may make this clinical problem 
less amenable to interventions with glycoprotein llbillla 
amagom~ts. The mechanism of coronary recoil (7YI. which 
may account for up to 4CfS of clinical rcsteoosis IWaIler B. 
personal communicationl. could not be cnp-ected to respond 
to platelet antagonists. Similarly. fibrocellulsr proliferation 
stimulated by the release of platelet alpha gromdes may not 
& markedly decreased by glycoprotein lIb/llla antagonists 
because of their inability to eliminate alpha granule secretion 
1%291 and because platelets adhering to the: subeodothelial 
surface lore nearly all oftheir alpha granule ,wiucts within 
40 min. whereas plstelets that aggregats onto adherent 
platelets penenlly rctoin their gannule~ 18Ctl. To the extent 
that orfaniration of mural thrombi play, a role in restcnosis. 
glycoprotem Ilb/llla receptor antagonists may be effective 
because of their nbility to decrease acute platelet mass 
adherent rt the site of angioplasty (16). However. the 
duration of treatment required to permanently inhibit mural 
rhmmbus formation in this setting is uncertain and may be 
greater than rhar easily achieved in the clinical selting. 
Convenely. early “passivation” of the stimulus for platelet 
deposition might obviate the need for treatment beyond 
approximately 24 h (14). 
Finally. borne “restcoosib” may actually represent pro- 
gression of underlying atheroma. Because antiplatelet reat- 
ment may retard progression of atherosclerosis (Xl). glyco- 
protein llbillla antagonists might have a salutary effect on 
ihis mechanism of restenosis. Thus. glycoprotein llblllla 
aotzaeoni\ts might be useful in treating some of the factors 
cm& rest&is. but would be expected to be inactive 
agSnTt others. Given the apparent multip!icity of mecha- 
nisms. no single agent is likely to prevent restenosis: there- 
fore, glycoprotrin llbillla antagonists. if clinical safety can 
anliphlelct agcntr lo integrm receptors on blood elcmenls 
other Ih;ln platelets Iwch ;I% the Mac-1 receploron activated 
monocyw IX?]) need to he clarified before these agents cart 
be wn,idcrcd fur widcapread cljnical upplw!ion. 
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